Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Eukaryotic Gene Expression
IF: 2.156 5-Year IF: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Print: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v26.i1.60
pages 49-62

Dual Role of p21 in the Progression of Cancer and Its Treatment

Amna Parveen
Pharmaceutical Resources Botany Laboratory, Department of Pharmacognosy, College of Pharmacy, Chung-ang University, Seoul, Republic of Korea; Department of Pharmaceutical Chemistry, Government College University Faisalabad, Pakistan
Muhammad Sajid Hamid Akash
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
Kanwal Rehman
Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
Whang Wan Kyunn
Pharmaceutical Resources Botany Laboratory, Department of Pharmacognosy, College of Pharmacy, Chung-ang University, Seoul, Republic of Korea

ABSTRACT

Cancer develops due to an imbalance between cell proliferation and cell death. Various mechanisms of carcinogenesis as well as of novel anticancer agents that could be targeted for the treatment of cancer have been proposed by different studies. Among these, p21 is recognized as a potent cyclin-dependent kinase inhibitor that facilitates cell-cycle arrest by interacting with different stimuli such as p53, DNA repair process, CDK, E2F1, MYC, PCNA, STAT3 AP4, proteasomes, K1F, CDX2, and ER-α. p21 acts both as a tumor-suppressor gene and an inhibitor of apoptosis by interacting with various molecules and transition factors. In this review, we discuss the complex role of p21 in the development of cancer and as a target in its treatment. We conclude that, in the future, the tumor-suppressor activity of p21 should be the focus of a novel treatment strategies, which may lead to the devolvement of new and selective anti-cancer agents for the targeted therapy of cancers.


Articles with similar content:

Therapeutic YY1 Inhibitors in Cancer: ALL in ONE
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Benjamin Bonavida
Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 1
Stavroula Baritaki, Kam C. Yeung, Benjamin Bonavida
Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Nicholas R. Galloway, Kathryn F. Ball, Nathan R. Wall, TessaRae Stiff
Oncogene-lnitiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 3-4
David T. Denhardt
Autophagy and Hallmarks of Cancer
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Namratha Sastry, Xuechao Wan, Angel A. Alvarez, Haizhong Feng, Shi-Yuan Cheng, Xiao Song, Bo Hu, Tianzhi Huang, Yongyong Yang